United Therapeutics (NASDAQ:UTHR) Posts Earnings Results, Beats Estimates By $0.41 EPS

United Therapeutics (NASDAQ:UTHR) released its quarterly earnings results on Wednesday. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41, Briefing.com reports. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.41 earnings per share.

Here are the key takeaways from United Therapeutics’ conference call:

• Positive Sentiment: United Therapeutics reported highly statistically significant results for the ADVANCE OUTCOMES study of ralinepag in PAH and submitted an NDA to the FDA, viewing the once-daily oral prostacyclin as a potential multibillion-dollar opportunity.
• Positive Sentiment: The company submitted an sNDA for nebulized Tyvaso in IPF after positive TETON results, with a potential 2027 approval; enrollment in the larger TETON PPF study is also nearly complete.
• Negative Sentiment: Second-quarter revenue was approximately $783 million, essentially flat sequentially and below management’s expectations. The company did not reaffirm or update its 2026 revenue-growth outlook, while nebulized Tyvaso remained pressured by increased competition.
• Positive Sentiment: Tyvaso DPI patient starts, referrals, total patients, and commercial patients reached record levels exiting the quarter, and a roughly doubled sales force began entering the field in July to improve physician reach and support second-half performance.
• Neutral Sentiment: United Therapeutics continues to advance its xenotransplantation pipeline, including UKidney, UThymoKidney, and EXPRESS-UHeart studies, while completing construction of commercial-scale facilities in Minnesota and Texas; however, these programs remain clinical-stage opportunities.

United Therapeutics Stock Performance

UTHR opened at $519.34 on Thursday. The stock has a market capitalization of $22.05 billion, a PE ratio of 19.17, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59. The stock’s 50 day moving average price is $540.37 and its 200-day moving average price is $533.71. United Therapeutics has a 52-week low of $292.34 and a 52-week high of $609.35.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics reported second-quarter adjusted earnings of $7.27 per share, exceeding analyst estimates of roughly $6.82–$6.86 and rising from $6.41 a year earlier. Net income also increased, signaling stronger profitability despite softer sales. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management highlighted the submission of two new drug applications, including ralinepag for rare pulmonary disease. Regulatory progress could expand the company’s pipeline and provide longer-term growth beyond its existing pulmonary arterial hypertension franchise. United Therapeutics Q2 Net Income Rises, Revenue Falls
• Neutral Sentiment: The earnings call and presentation gave investors additional detail on quarterly performance, pipeline development and upcoming regulatory milestones. Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $648, above recent trading levels. United Therapeutics Corporation Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter revenue declined approximately 2% year over year to $783.3 million, compared with $798.6 million a year earlier. The sales decline suggests that earnings growth was driven more by profitability and cost dynamics than by accelerating top-line demand. United Therapeutics Reports Q2 Earnings: Key Metrics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares worth about $4.9 million, reducing her direct ownership by 2.84%. While the sale may be routine, insider selling can create a modest overhang for investor sentiment. United Therapeutics CEO SEC Filing

Insiders Place Their Bets

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the transaction, the director directly owned 450 shares in the company, valued at approximately $247,765.50. This represents a 41.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,432,054.58. This represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 474,533 shares of company stock valued at $261,703,072 in the last ninety days. 8.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC bought a new position in United Therapeutics in the second quarter worth $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its position in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the period. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research reports. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, July 31st. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Royal Bank Of Canada boosted their target price on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $648.33.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.